ArticleDiscover oncology2025
Genetically predicted interleukin 7 levels and neuroblastoma risk combined with analysis of radiation therapy timing effects.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe causal relationship between interleukin-7 levels and neuroblastoma risk remains unclear, and optimal radiation therapy timing lacks definitive evidence. This study investigated causal associations using Mendelian randomization while examining radiation therapy timing effects.
methodsWe conducted two-sample Mendelian randomization analysis using GWAS summary statistics for interleukin-7 levels and neuroblastoma with three SNPs as instrumental variables. Multiple MRmethods included inverse variance weighted (IVW), MR-Egger, weighted median, and mode approaches. Additionally, 1,007 neuroblastoma patients from SEER database (2000-2018) were analyzed comparing preoperative (n = 416) versus postoperative (n = 591) radiation therapy using propensity score matching and Cox regression models.
resultsMendelian randomization revealed significant positive causal association between elevated interleukin-7 levels and increased neuroblastoma risk. The IVW method showed higher interleukin-7 levels associated with 3.6-fold increased odds (OR = 3.585, 95% CI: 1.216-10.575, p = 0.021). In clinical analysis, preoperative radiation demonstrated superior survival outcomes with 27% mortality reduction (HR = 0.73, 95% CI: 0.55-0.97, p = 0.031). Subgroup analysis revealed significant racial differences, with White patients deriving greatest benefit from preoperative radiation (HR = 0.57, 95% CI: 0.42-0.78, p < 0.001).
resultsThis study provides evidence for causal relationship between interleukin-7 levels and neuroblastoma risk, suggesting inflammatory pathways' role in pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.